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Abstract
The neuregulin 1 (NRG1) promoter single nucleotide polymorphism (SNP) rs6994992 has shown
association with decreased activation of frontal and temporal lobe regions, increased risk of
psychosis, and decreased premorbid IQ. This SNP is part of a putative schizophrenia risk-
associated haplotype and was associated with increased expression of the type IV transcript in
postmortem tissue. We tested for association between rs6994992 and chronic schizophrenia by
genotyping 738 cases from the Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE) and 733 matched controls. We further tested for associations with age at onset and
baseline neurocognition in cases with schizophrenia reasoning that these phenotypes might yield
results similar to those seen for premorbid IQ. Affection status was weakly associated with
rs6994992 genotypes and trended towards association under a recessive model. This association
did not survive correction for multiple comparisons and was in the opposite direction than has
been reported. There was no association between rs6994992 and age at onset, an estimate of
premorbid IQ, or neurocognition at study baseline. We were unable to replicate previous
associations of rs6994992 with schizophrenia and, moreover, did not find significant associations
with age of onset, an estimate of pre-morbid IQ, or neurocognition.
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In a recent Nature Neuroscience paper, Hall and colleagues (Hall et al., 2006) investigated
the effects of rs6994992, a neuregulin 1 (NRG1) promoter single nucleotide polymorphism
(SNP), in Scottish subjects at high risk of schizophrenia by virtue of having at least two
affected family members. They demonstrated significant association of this polymorphism
with decreased activation of frontal and temporal lobe regions, increased risk of psychosis,
and decreased premorbid IQ. The effect of this SNP was exceptional – 12 of 12 subjects
with the TT genotype developed psychotic symptoms compared to 19/40 with CT and 12/27
with CC genotypes. Moreover, rs6994992 (also known as SNP8NRG243177) is part of a
putative schizophrenia risk-associated haplotype (Li et al., 2006; Stefansson et al., 2003;
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Stefansson et al., 2002) that is predicted to alter the putative binding sites for three
transcription factors and was associated with increased expression of the type IV transcript
in postmortem tissue (Law et al., 2006). Given that the effect of rs6994992 was so marked,
we tested for association between rs6994992 and chronic schizophrenia by genotyping 738
cases and 733 matched controls. We further tested for associations with age at onset and
baseline neurocognition in cases with schizophrenia reasoning that these phenotypes might
yield results similar to those of Hall et al (2006).
We genotyped rs6994992 (chr8:31,615,123, NCBI Build 35) in 738 participants (74% male,
26% female; 57% European ancestry, 29% African, 14% other) in CATIE (Clinical
Antipsychotic Trials of Intervention Effectiveness), a double-blinded randomized clinical
trial of typical and atypical antipsychotics under controlled conditions with follow-up for as
long as 18 months, and in which all subjects provided informed consent under IRB approval
(Lieberman et al., 2005). Briefly, inclusion criteria required a definite diagnosis of
schizophrenia, previous antipsychotic treatment, age 18–65 years, clinical decision that oral
medication was appropriate, adequate decisional capacity and provision of written informed
consent. Exclusion criteria essentially stipulated that participation was safe and clinically
reasonable (Stroup et al., 2003). The construction, implementation, and analyses of the
neurocognitive data from CATIE are described at length elsewhere (Keefe et al., 2006;
Keefe et al., 2003). Briefly, this battery assessed aspects of neurocognitive function that are
robustly associated with schizophrenia, that could plausibly improve with treatment, and
which were practical to do in a large patient sample treated in “real world” clinical care
settings. We tested for association with two variables: WRAT-3 score (a proxy measure of
premorbid IQ) (Griffin et al., 2002) and a composite neurocognitive score (Keefe et al.,
2006).
There were 733 control subjects (67% male, 33% female; 56% European ancestry, 30%
African, 14% other), group-matched to cases by age, sex, and self-reported race. Controls
were ascertained from a US national sampling frame as part of the Gejman MGS study
(MH059571). Controls were collected by Knowledge Networks (KN), a survey and market
research company whose panel contains approximately 60,000 households (>120,000
unrelated adults) that were selected by random digit dialing. KN provided financial
incentives to its panel members for participation in web-based surveys. The panel is
representative of the US population (except for a slight bias toward higher income and
education). Subjects were sampled proportionally from 25 major population areas.
Exclusion criteria were self-reported history of psychotic or bipolar disorders. Written
informed consent was obtained from all participants.
The SNP rs6994992 was genotyped using TaqMan (Livak 1999) blind to all phenotypic data
and passed quality control – minor allele frequency agreed with published reports (Li et al.,
2006), perfect agreement of 99 duplicated samples with originals, overall no-call proportion
was 0.014, and genotype frequencies were consistent with Hardy-Weinberg equilibrium
overall (p=0.48) and in the major ancestry groups (AFR p=0.49 and EUR p=0.48).
Association results are shown in the Table. Affection status was weakly associated with
rs6994992 genotypes and trended towards association under a recessive model (TT versus
CT/TT). This association did not survive correction for multiple comparisons and was in the
opposite direction than has been reported (i.e., T allele less prevalent in cases) (Li et al.,
2006). Within the schizophrenia sample, we saw no association between rs6994992 and age
at onset, an estimate of premorbid IQ, or neurocognition at study baseline.
In conclusion, we were unable to replicate previous associations of rs6994992 with
schizophrenia and, moreover, did not find significant associations with age of onset, an
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estimate of pre-morbid IQ, or neurocognition. Our study had 80% power to detect a
genotypic relative risk of 1.29 or larger (log additive model, allele frequency 0.4, and two-
tailed p=0.01) (Gauderman 2002). It is important to note the dissimilarities of this sample
and phenotypes to that of Hall et al (2006) as we studied individuals with chronic
schizophrenia and used different phenotype measures.
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